Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: Meta-analysis of 5 trials
- 17 April 2014
- journal article
- research article
- Published by Elsevier in Journal of Hepatology
- Vol. 61 (2) , 200-209
Abstract
No abstract availableKeywords
Funding Information
- Merck
This publication has 16 references indexed in Scilit:
- Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890Journal of Hepatology, 2013
- 60 SVR12 RATES AND SAFETY OF TRIPLE THERAPY INCLUDING TELAPREVIR OR BOCEPREVIR IN 221 CIRRHOTIC NON RESPONDERS TREATED IN THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC)Journal of Hepatology, 2013
- Efficacy and safety of boceprevir plus peginterferon–ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosisJournal of Hepatology, 2013
- How to optimize HCV therapy in genotype 1 patients with cirrhosisLiver International, 2013
- Boceprevir With Peginterferon Alfa-2a–Ribavirin Is Effective for Previously Treated Chronic Hepatitis C Genotype 1 InfectionClinical Gastroenterology and Hepatology, 2013
- 836 Sustained Virologic Response (SVR) in Prior Peginterferon/Ribavirin (PR) Treatment Failures After Retreatment With Boceprevir (BOC) + PR: the Provide Study Interim ResultsGastroenterology, 2012
- Boceprevir for Untreated Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2011
- Boceprevir for Previously Treated Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2011
- Now there are many (stages) where before there was oneHepatology, 2010
- Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosisHepatology, 2007